Zobrazeno 1 - 10
of 205
pro vyhledávání: '"Ross, L"'
Autor:
Eirini P. Papapetrou, Oliver Soehnlein, Andriana G. Kotini, Ying Wei, Ross L. Levine, David G. Thomas, Marit Westerterp, Joachim Pircher, Hans-Willem Snoeck, Steffen Massberg, Alan R. Tall, Larry Luchsinger, Nan Wang, Chenyi Xue, Carlos Silvestre-Roig, Tong Xiao, M. Yalcinkaya, Trevor P. Fidler, Peter Libby, Christian Schulz, Mohammad Ali Hajebrahimi, Brian Hardaway, Wenli Liu, Muredach P. Reilly, Benjamin L. Ebert, Sandra Abramowicz
Publikováno v:
The journal of cardiovascular aging
Nature, 592(7853), 296-301. Nature Publishing Group
Nature
Nature, 592(7853), 296-301. Nature Publishing Group
Nature
Clonal haematopoiesis, which is highly prevalent in older individuals, arises from somatic mutations that endow a proliferative advantage to haematopoietic cells. Clonal haematopoiesis increases the risk of myocardial infarction and stroke independen
Autor:
Anthony F. Daniyan, Maximilian Stahl, Martin S. Tallman, Alexander Chan, Aaron D. Viny, Sheng F. Cai, Christopher Famulare, Eytan M. Stein, Kamal Menghrajani, Jacob L. Glass, Bernadette M. Cuello, Mikhail Roshal, Omar Abdel-Wahab, Troy Z. Horvat, Aaron D. Goldberg, Andriy Derkach, Amber C. King, Wenbin Xiao, Ross L. Levine
Publikováno v:
Blood Adv
Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML). Although these combinations are also commonly used in r
Autor:
Jordan Chervin, Ross L. Levine, Tara L. Lin, Ying Huang, William Blum, Sonja Marcus, Tibor Kovacsovics, Ashley O. Yocum, Franchesca Druggan, Gary J. Schiller, Brian J. Druker, Mona Stefanos, Uma Borate, Matthew C. Foster, Mark R. Litzow, John C. Byrd, Nyla A. Heerema, Robert H. Collins, Abigail B. Shoben, Wendy Stock, Leonard Rosenberg, Amy Burd, Michael Boyiadzis, James M. Foran, Rebecca L. Olin, Jo-Anne Vergilio, Prapti A. Patel, Maria R. Baer, Timothy L. Chen, Eytan M. Stein, Alice S. Mims
Publikováno v:
Blood. 136:27-30
Background: ENA is an oral, selective inhibitor of IDH2 approved for the treatment (Tx) of patients (pts) with relapsed/refractory IDH2 mutated (IDH2m) AML. Here we report the results of a Phase 2 expansion and Phase 1b of the Beat AML Master Trial P
Autor:
Eneda Toska, Emiliano Cocco, Jane Park, Jorge S. Reis-Filho, Ross L. Levine, Pier Selenica, Jordan E. Otto, Maurizio Scaltriti, Fan Wu, Clayton K. Collings, Lorenzo Ferrando, Komal Jhaveri, Carmen Chan, Erik Ladewig, Huiyong Zhao, José Baselga, Yanyan Cai, Sagar Chhangawala, Mirna Sallaku, Cristian Serna-Tamayo, Pedram Razavi, Richard Koche, Andrew R. D’Avino, Christina S. Leslie, Guotai Xu, Alison Zhao, Arnaud Da Cruz Paula, Yuanming Cheng, Cigall Kadoch, Xuan Qu, Matthew Witkin
Publikováno v:
Nat Genet
Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER(+)) breast cancer. We identify that ARID1A inactivating mutations are present at a hi
Autor:
Charyguly Annageldiyev, Nicole R. Keasey, Emily Sullivan, Paul T. Toran, Hong Gang Wang, Regina M. Ondrasik, Su Fern Tan, Andrea L. Cote, Tye G. Deering, Todd E. Fox, David J. Feith, Brian M. Barth, Timothy J Brown, Stephan T. Stern, Mark Kester, David F. Claxton, Thomas P. Loughran, Vasiliki Papakotsi, Arati Sharma, Ross L. Levine, David B. Needle, Junjia Zhu, Sriram S. Shanmugavelandy, Aaron D. Viny, Viola Devine, Weiyuan Wang, Jason Liao
Publikováno v:
Blood Advances. 3:2598-2603
Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.
Autor:
Garnet L. Anderson, Rowan T. Chlebowski, Michael S. Simon, Jane A. Cauley, JoAnn E. Manson, Thomas E. Rohan, Wendy E. Barrington, Lewis H. Kuller, Kathy Pan, Margery Gass, Marcia L. Stefanick, Maryam Sattari, Dorothy S. Lane, Ross L. Prentice, Karen C. Johnson, Electra D. Paskett, Aaron K. Aragaki
Publikováno v:
Obstetrical & Gynecological Survey. 75:737-739
Importance The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials. Objective To assess the association of prior randomized use of estrogen plus
Autor:
Qin Yang, Richard Koche, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman, Erin McGovern, Christopher Famulare, Maria E. Figueroa, Raajit K. Rampal, Ross L. Levine
Publikováno v:
Blood. 136:18-20
Methylation profiling in myeloid malignancies such as Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) has demonstrated the ability to define distinct biological and clinical subgroups, including predicting which patients will
Autor:
Stefan Dirnhofer, Katharina Leonards, Gregor Hutter, Ross L. Levine, Jakob Passweg, Simona Stivala, Heidi E. L. Lischer, Sarah Jungius, Benjamin G. Neel, Alice Santopolo, Dimitrios A. Tsakiris, Sime Brkic, Sara C. Meyer, Matthias S. Dettmer, Jakub Szybinski
Publikováno v:
Leukemia
Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2
Brkic, Sime; Stivala, Simona; Santopolo, Alice; Szybinski, Jakub; Jungius, Sarah; Passweg, Jakob R; Tsakiris, Dimitrios; Dirnhofer, Stefan; Hutter, Gregor; Leonards, Katharina; Lischer, Heidi E L; Dettmer, Matthias S; Neel, Benjamin G; Levine, Ross L; Meyer, Sara C (2021). Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 35(10), pp. 2875-2884. Springer Nature 10.1038/s41375-021-01391-2
Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes efficacy. We hypothesized that dual targeting of JAK2 and ERK1/2 could enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5381ce2f46cabbd22562ed7e1b8c38a9
Autor:
Shira E. Eisman, Ross L. Levine, Wenbin An, Bing Li, Benjamin H. Durham, Maria Pinzon-Ortiz, Barbara Spitzer, Aishwarya Krishnan, Shoron Mowla, Andriy Derkach, Gary J. Vanasse, Xianhui Rong, Raajit K. Rampal, Sean M. Devlin, Justin T. Whitfield, Keith B. Cordner, Tyler Longmire, Amritha Varshini Hanasoge Somasundara, Zhu A Cao, Richard Koche
Publikováno v:
Clin Cancer Res
Purpose: The JAK1/2 inhibitor ruxolitinib has demonstrated significant benefits for patients with myeloproliferative neoplasms (MPN). However, patients often lose response to ruxolitinib or suffer disease progression despite therapy with ruxolitinib.
Autor:
Cordelia Selomulya, Liam Michael Powles, Kirsty Wilson, Charles Wai Chung Ma, Sue D. Xiang, Magdalena Plebanski, Ross L. Coppel
Publikováno v:
Vaccines
Volume 8
Issue 4
Vaccines, Vol 8, Iss 651, p 651 (2020)
Volume 8
Issue 4
Vaccines, Vol 8, Iss 651, p 651 (2020)
Vaccines against blood-stage malaria often aim to induce antibodies to neutralize parasite entry into red blood cells, interferon gamma (IFN&gamma
) produced by T helper 1 (Th1) CD4+ T cells or interleukin 4 (IL-4) produced by T helper 2 (Th2) c
) produced by T helper 1 (Th1) CD4+ T cells or interleukin 4 (IL-4) produced by T helper 2 (Th2) c